Clinical Trial Update: Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment [Phase 2]

View source ↗

Summary

This Phase 2 trial update assesses the tolerance and efficacy of subcutaneous low-dose rituximab as consolidation therapy for chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Institut Paoli-Calmettes | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: UNKNOWN